Neumora Therapeutics faced a significant stock price decrease after its lead drug navacaprant failed in a Phase III trial for major depressive disorder. Despite the setback, the company is analyzing data trends and exploring other avenues for drug development in neurodegenerative and neuro-psychiatric diseases.